MedTrace Logo

Ketohexokinase Isoforms in Endometrial Cancer.

NCT03931265 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2023-09-15

No results posted yet for this study

Summary

Our preliminary analysis with clinical database suggested that, in patients with type I endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. To understand the importance of ketohexokinase expression and isoform switch during the development of type I endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.

Conditions

Interventions

DIAGNOSTIC_TEST

ketohexokinase

Check the isoforms of ketohexokinase in the specimen of endometrial cancer

Sponsors & Collaborators

  • Gynecologic Oncology Group

    collaborator NETWORK

  • Far Eastern Memorial Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-11
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03931265 on ClinicalTrials.gov